1132935-63-7

1132935-63-7 structure

Name: ABT-333
Chemical Name: dasabuvir
CAS Number: 1132935-63-7
Molecular Formula: C₂₆H₂₇N₃O₅S
Molecular Weight: 493.575
Catalog: Signaling Pathways Anti-infection HCV
Create Date: 2016-02-27 12:31:06
Modify Date: 2024-01-05 18:37:45
Dasabuvir (ABT-333) is a nonnucleoside inhibitor of the RNA-dependent RNA polymerase encoded by the HCV NS5B gene, inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates, with IC50 between 2.2 and 10.7 nM.

Name	dasabuvir
Synonyms	ABT-333 Methanesulfonamide,N-(6-(5-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-3-(1,1-dimethylethyl)-2-methoxyphenyl)-2-naphthalenyl) ABT333 N-{6-[5-(2,4-Dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-2-methoxy-3-(2-methyl-2-propanyl)phenyl]-2-naphthyl}methanesulfonamide Methanesulfonamide, N-[6-[5-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-3-(1,1-dimethylethyl)-2-methoxyphenyl]-2-naphthalenyl]- N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide UNII:DE54EQW8T1 Dasabuvir

Description	Dasabuvir (ABT-333) is a nonnucleoside inhibitor of the RNA-dependent RNA polymerase encoded by the HCV NS5B gene, inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates, with IC50 between 2.2 and 10.7 nM.
Related Catalog	Signaling Pathways >> Anti-infection >> HCV Research Areas >> Infection
Target	IC50: 2.2-10.7 nM (NS5B polymerase)[1]
In Vitro	Dasabuvir (ABT-333) is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases. Dasabuvir (ABT-333) inhibits the polymerase enzymatic activity of genotype 1 laboratory strain enzymes (H77, BK, N, and Con1 strains), as well as enzymes produced from polymerase genes from HCV genotype 1-infected subjects, with IC50s between 2.2 and 10.7 nM. Dasabuvir (ABT-333) inhibits replication of HCV subgenomic replicons in cell culture assays, with EC50 values of 7.7 and 1.8 nM against genotype 1a (H77) and 1b (Con1), respectively. In the presence of 40% human plasma, there is a 12- to 13-fold decrease in inhibitory potency, yielding EC50s of 99 and 21 nM for HCV genotype 1a (H77) and 1b (Con1) replicons, respectively[1].
References	[1]. Kati W, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2015 Mar;59(3):1505-11.

Hazard Codes	Xi

1132940-53-4

1132940-88-5

~24%

1132935-63-7

Literature: ABBOTT LABORATORIES Patent: WO2009/39134 A1, 2009 ; Location in patent: Page/Page column 109 ;

1132940-49-8

1132940-88-5

1132935-63-7

Literature: ABBOTT LABORATORIES Patent: WO2009/39127 A1, 2009 ; Location in patent: Page/Page column 180 ;

3144-09-0

1355646-97-7

1132935-63-7

Literature: ABBOTT LABORATORIES Patent: US2012/14913 A1, 2012 ; Location in patent: Page/Page column 29-30 ; US 20120014913 A1